Home    Back

Infusion of adr-001 (mesenchymal stem cell)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
66IgA nephropathy1

66. IgA nephropathy    [ 199 clinical trials,   214 drugs,   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways]
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04342325
(ClinicalTrials.gov)		June 15, 20208/4/2020The Clinical Trial of ADR-001 for IgA NephropathyOpen-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) NephropathyGlomerulonephritis , IGABiological: infusion of ADR-001 (Mesenchymal stem cell)Nagoya UniversityRohto Pharmaceutical Co., Ltd.Recruiting20 YearsN/AAll12Phase 1Japan